DRIVIN G ROWTH - Dr. Reddy's
DRIVIN G ROWTH - Dr. Reddy's
DRIVIN G ROWTH - Dr. Reddy's
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
52<br />
management discussion<br />
and analysis<br />
launch of new products such as gatifloxacin<br />
and clopidogrel sesquihydrate in the<br />
domestic market, coupled with<br />
increase in sales of nizatidine,<br />
ciprofloxacin and ranitidine in<br />
the international markets.<br />
During the year, the Company<br />
filed 8 drug master files (DMFs)<br />
in the US, taking the total to 26,<br />
as well as 34 dossiers in Europe. Table 3<br />
gives the sale of the top APIs and their<br />
share in total APIs revenues.<br />
As far as international revenue of APIs is<br />
concerned, <strong>Dr</strong>. Reddy’s supplies to the<br />
world’s largest generic players. With the<br />
anticipated growth in the global generics<br />
business after 2005 — when a large number<br />
of formulations go off-patent — the<br />
Company’s APIs business should see<br />
significant growth.<br />
BRANDED FORMULATIONS<br />
THE BRANDED FORMULATION<br />
business recorded a 23 per cent increase<br />
— in revenue to Rs. 6,057 million in 2001-<br />
02, compared to Rs. 4,938 million during the<br />
previous year. International revenue grew<br />
by 55 per cent, driven by a 100 per cent<br />
increase in sales to Russia. Revenue from<br />
the Indian market grew by 11 per cent,<br />
primarily due to performance of top brands<br />
such as Nise, Stamlo and Omez, as well as<br />
19 new brand launches which accounted<br />
for 50 per cent of the total growth. Some of<br />
the new brands were Gaity, Clamp, Ebiza,<br />
Plagril, Fiona and Zubair. Sale of the dental<br />
brands acquired from Group<br />
Pharmaceuticals commenced in the fourth<br />
quarter of 2001-02, and contributed Rs. 23<br />
million to Indian revenue.<br />
According to ORG, <strong>Dr</strong>. Reddy’s is ranked<br />
Table 4<br />
|<br />
India Top-10 brands<br />
RS. MILLION<br />
2001-02 AS A % 2000-01 AS A %<br />
Nise 588 14.5% 445 14.5%<br />
Omez 463 11.5% 440 11.5%<br />
Stamlo 244 6.0% 233 6.0%<br />
Ciprolet 219 5.4% 275 5.4%<br />
Enam 143 3.5% 146 3.5%<br />
Stamlo Beta 129 3.2% 110 3.2%<br />
Antoxid 110 2.7% 97 2.7%<br />
BIO E 87 2.2% 90 2.2%<br />
Reclide 53 1.3% 59 1.3%<br />
GLA 96 2.4% 92 2.4%<br />
Others 1,910 47.2% 1,655 47.2%<br />
Total 4,042 100.0% 3,642 100.0%<br />
DR. REDDY’S LABORATORIES LTD. | MANAGEMENT DISCUSSION AND ANALYSIS | ANNUAL REPORT 2001-2002